



THIS PRESS RELEASE MAY NOT BE PUBLISHED, DISSEMINATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN

## Partial exercise of over-allotment option

### *Capital increase of around €27.8 million during the IPO Implementation of a liquidity contract with French Broker Gilbert Dupont*

**Nîmes, France, January 5<sup>th</sup>, 2018** - Advicenne, a specialist pharmaceutical company focused on the development of paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces today the partial exercise of the over-allotment option by Gilbert Dupont (the “Stabilization Manager”) acting on behalf of Gilbert Dupont and NIBC (the “Joint Global Coordinators”) at close to 72% in connection with its Initial Public Offering (IPO) on Euronext’s regulated market in Paris.

The partially exercised over-allotment option enabled the issue of 59,648 additional new shares at the Offer Price of €14.03 for a total amount of € 836,861.44. As a result, the total number of shares issued by Advicenne during the IPO amounts to 1,984,096 shares, representing about € 27.8 million.

Furthermore, in accordance with Article 6 of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016, the Stabilization Manager, has performed stabilization operations on Advicenne shares listed on Euronext Paris (ISIN Code: FR0013296746 ; Symbol: ADVIC) as follows:

- stabilization began on December 6, 2017;
- the final stabilization operation was carried out on January 4, 2018;
- the stabilization operations occurred under the following conditions:

Date	Lowest price (in €)	Highest price (in €)
06/12/2017	13.90	14.00
07/12/2017	13.83	14.00
08/12/2017	13.88	13.90
11/12/2017	13.95	14.00
12/12/2017	13.95	14.00
13/12/2017	13.92	13.98
14/12/2017	13.83	14.00
15/12/2017	13.98	14.00
18/12/2017	13.88	13.98
19/12/2017	13.75	13.93
20/12/2017	13.80	13.93
21/12/2017	13.85	14.01
22/12/2017	13.98	14.01
27/12/2017	13.90	14.00
28/12/2017	13.91	13.94
29/12/2017	13.91	13.99
02/01/2018	13.98	14.01
03/01/2018	14.02	14.02
04/01/2018	14.00	14.02

Advicenne also announces that it has entered into a liquidity contract with French broker Gilbert Dupont that complies with the code of ethics issued by the AMAFI. The liquidity contract will run over a one-year period, starting the January 4, 2018, and will renew automatically. Its purpose is to promote the shares of Advicenne on Euronext Paris. For the implementation of this contract, the sum of € 300,000 in cash has been allocated to the liquidity account.

### Evolution of the share capital following the partially exercised over-allotment option

Following the partially exercised over-allotment option, the share capital of Advicenne will amount to 1,612,468.80 euros divided into 8,062,344 shares allocated (to the best of the Company's knowledge) as follows:

	Number of shares	% of share capital and voting rights <sup>(1)</sup>
Luc-André Granier*	250,000	3,10%
Caroline Roussel-Maupetit	146,885	1,82%
Ludovic Robin	28,971	0,36%
Nathalie Lemarié	1,069	0,01%
<b>Total executive directors</b>	<b>426,925</b>	<b>5,30%</b>
<b>Total employees/committee members/consultants</b>	<b>44,519</b>	<b>0,55%</b>
IXO Private Equity* <sup>(2)</sup>	1,462,082	18,13%
Bpifrance Investissement* <sup>(3)</sup>	2,249,568	27,90%
Cemag Invest*	689,212	8,55%
Irdi Soridec Gestion* <sup>(2)</sup>	435,511	5,40%
Marie-Odile Humblet	597,249	7,41%
Jean-Pierre Lefoulon*	370,650	4,60%
Françoise Brunner-Ferber*	317,393	3,94%
Other investors	380,179	4,72%
<b>Total investors</b>	<b>6,501,844</b>	<b>80,64%</b>
<b>Free float</b>	<b>1,089,056</b>	<b>13,51%</b>
<b>TOTAL</b>	<b>8,062,344</b>	<b>100,00%</b>

\* Company Directors (administrators)

- (1) the percentage of voting rights being identical to the percentage of the share capital held, it must be noted however that, as from the December 5, 2019, fully paid-up shares for which it will be justified a nominative registration in the name of the same shareholder for at least two years from that date will have double voting rights
- (2) through the funds of which it is the asset management company
- (3) through the FPCI Innobio, of which it is the asset management company

### Upcoming timetable

<b>8 January 2018</b>	Settlement-delivery of shares issued within the partially exercised over-allotment option
-----------------------	---

### Financial Intermediaries

*Joint Global Coordinators, Joint Lead Managers and Joint Bookrunners*



## About Advicenne

Advicenne is a late-stage pharmaceutical company focusing on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company's most advanced product is ADV7103 which has shown positive results in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). ADV7103 is also being developed in a second indication for the treatment of Cystinuria, an inherited renal tubulopathy and is expected to begin a pivotal phase III clinical trial in this indication in Europe in 2018.

In addition to ADV7103, the Company has a portfolio of clinical and pre-clinical products targeting critical unmet needs in nephrology and neurology in collaboration with Key Opinion Leaders.

Additional information about Advicenne is available through its website: [www.advicenne.com](http://www.advicenne.com)

## Contacts:

### Advicenne

LA Granier, S Delbaere, J Rachline  
[investors@advicenne.com](mailto:investors@advicenne.com)  
+33 (0)4 66 05 54 20

### Media relations

### Citigate Dewe Rogerson

David Dible, Sylvie Berrebi, Marine Perrier (London)  
Laurence Bault, Alexandre Dechaux (Paris)  
[advicenne@citigatedewerogerson.co.uk](mailto:advicenne@citigatedewerogerson.co.uk)  
+44 (0) 20 7638 9571 / +33 (0)1 53 32 78 87

## Legal Disclaimer:

*This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States of America, Canada, Australia or Japan.*

*No communication and no information in respect of the offering or of Advicenne of the shares may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken outside of France in any jurisdiction where such steps would be required. The offering and subscription of the Shares may be subject to specific legal or regulatory restrictions in certain jurisdictions*

*The distribution of this document and the issue as well the subscription of Advicenne's shares may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.*

*This press release is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the "**Prospectus Directive**").*

*With respect to the member States of the European Economic Area which have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State other than France. As a result, the securities may not and will not be offered in any relevant member State other than France except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member State, or under any other circumstances which do not require the publication by Advicenne of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.*

*This press release does not constitute an offer to purchase or to subscribe for securities in the United States or in any other jurisdiction.*

*The securities referred to herein may not be offered or sold in the United States of America absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended. Advicenne does not intend to register all or any portion of the offering of the securities in the United States of America or to conduct a public offering of the securities in the United States of America.*

*This communication does not constitute an offer of the securities to the public in the United Kingdom. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “**Relevant Persons**”). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.*